Covalent inhibitors represent a class of small molecules that form irreversible or quasi‐irreversible bonds with their protein targets, offering enhanced potency, prolonged duration of action and the ...

BUFFALO, N.Y. — One class of drugs that has shown promise in treating diseases ranging from lung cancer to COVID-19 are targeted covalent inhibitors (TCIs). These small molecule drugs form covalent ...

Advancements in drug design have resulted in resurging interest in drugs that form covalent bonds with their targets, often referred to as targeted covalent inhibitors. Covalent drugs have the ...

Researchers at Baylor College of Medicine have developed a powerful new data analysis method named COOKIE-Pro (Covalent Occupancy Kinetic Enrichment via Proteomics) that provides a comprehensive, ...

In the battle against B-cell cancers, drugs that target the enzyme Bruton tyrosine kinase (BTK) have transformed treatment. Before the first BTK inhibitor, ibrutinib, came on the market in 2013, ...

Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a novel series of orally available covalent ...

Matchpoint Therapeutics Inc. and Novartis AG have entered into an exclusive option and license agreement to develop and commercialize oral covalent inhibitors targeting a transcription factor linked ...

Please provide your email address to receive an email when new articles are posted on . The FDA will permit the COVALENT-111 and COVALENT-112 trials to continue following a clinical hold. Elevated ...

BH-30643 has demonstrated encouraging clinical activity against diverse EGFR genotypes and on-target resistance in heavily pretreated Phase 1 ...

Human cancer cells cultures in the lab of David Heppner. Heppner's team recently found that faster binding for targeted covalent inhibitor drugs was linked to greater potency, but only to a certain ...